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A significant interest lies in reliably quantifying
adipose tissue. Quantifying visceral adipose tissue
accurately and reliably allows for better cardiovascular
and metabolic risk stratification of patients and may be
beneficial at the community level. Visceral adipose
tissue quantification may also serve to measure the
effectiveness of pharmacotherapy or physical activity
regimens in targeting visceral adipose tissue, thus
serving as a therapeutic endpoint. 
Various methods to quantify visceral adipose tissue
directly by expensive magnetic resonance imaging and
radiation-exposing computed tomography, as well as
indirectly by anthropometric measures (e.g., waist-
circumference, body-mass index) exist (6-9, 27).
Magnetic resonance imaging is the gold standard
technique to accurately measure visceral adiposity
although there is some concern about the accuracy of
actual visceral adiposity content based on single slice
sampling  (i.e., whole body magnetic resonance
imaging scan is the true gold standard) (7, 10). Waist-
circumference as measure of visceral obesity may be
less reliable in older persons (11, 12). Also, waist-
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is briefly reviewed. Areas of the technique requiring further study are identified.
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INTRODUCTION
Metabolic and cardiovascular diseases are well
known to be more prevalent in obese individuals than
non-obese individuals (1). More specifically, increased
visceral adipose tissue, the fat that surrounds the
internal organs (e.g., heart, intestines) in the cavities of
the body, predicts an unfavorable cardiovascular and
metabolic risk profile (1-5). For example, visceral
adiposity is strongly correlated with diabetogenic
features (e.g., impaired insulin sensitivity, increased
insulin levels), atherogenic features (e.g., increased
triglycerides, decreased high density lipoproteins), pro-
thrombotic factors (e.g., increased fibrinogen, Factor
VII, plasminogen activator inhibitor 1) and pro-
inflammatory cytokines (e.g., interleukin-6 [IL-6] and
tumour necrosis factor-a [TNF- a]) (1-5).Echocardiographic Assessment of Epicardial Adipose Tissue 27 Vol. 10  No. 1
circumference may be a better measure of subcutaneous
rather than visceral obesity (11, 12). Anthropometric
techniques requiring measurement of the waist (e.g.,
waist-circumference, waist-to-hip ratio) may not
account for possibly confounding subcutaneous adipose
tissue especially in more obese individuals though waist
circumference is considered an accepted measure of
intra-abdominal adiposity (11, 12, 13). Body-mass
index, an anthropometric measure of visceral adiposity
is suggested to be a poorer indicator of cardiovascular
risk than waist-circumference across ethnicities,
suggesting that body-mass index may not be a very
good measure of visceral obesity (14).  
In light of the limitations, lack of practicality of
existing methods and the recognition that more reliable
measures of visceral adiposity are needed, Iacobellis et
al. proposed the direct measurement of epicardial
adipose tissue thickness via echocardiography as a
marker for visceral adiposity (15).
In this article, we review epicardial adipose tissue's
basic characteristics, method of clinical assessment, and
reliability in measuring visceral adiposity, as well as
identify areas that need further study. 
STRUCTURE AND FUNCTION OF EPICARDIAL
ADIPOSE TISSUE
Adapted from a recent review on epicardial adipose
tissue's relationship with the heart, Figure 1 illustrates
the macroscopic appearance of adipose tissue on a
normal and hypertrophied heart (16). Typically, normal
fat distributions in the heart are restricted to the grooves
between the atrium and ventricles, between the
ventricles and along the coronary arteries (16). As the 
mass of epicardial adipose tissue  increases, the
ventricular surfaces become covered with adipose tissue
(16). Figure 2 shows the massive amount of epicardial
adipose tissue that is deposited between the pericardium
and heart in an obese patient undergoing coronary artery
bypass. 
Epicardial adipose tissue is suspected to directly
interact with the adjacent myocardial tissue. Both
tissues share the same coronary blood supply and no
fascia-like structure separates the epicardial adipose
tissue from myocardium (17).
The specific function of epicardial adipose tissue is
yet to be determined though it is known to be very
active (e.g., considered a secretory organ) (18). The
tissue is not known to serve to protect the heart from
blunt trauma (16). Interestingly, though the tissue is
thought to be important, the tissue does not exist in
laboratory mice or rats (19). Marchington's animal
experimental studies showed that the principle
difference between epicardial adipose tissue and other
visceral adipose tissues is its greater capacity for free
fatty acid release (19). Thus, epicardial adipose tissue
may act as a local energy supply for the myocardium or
buffer against toxic levels of free fatty acids (19).
Epicardial adipose tissue is a very active endocrine
organ and may have an effect on local coronary artery
health. For example, epicardial adipose tissue is shown
to express various inflammatory factors such as IL-
1beta, IL-6, MCP-1 (Monocyte chemotactic protein-1),
and TNF-alpha mRNA in high risk cardiac patients
(e.g., coronary artery disease) (20, 21). The tissue also
secretes adiponectin, a serum protein known to be
secreted exclusively by adipose tissues, with anti-
inflammatory and anti-atherogenic properties (18, 22).
However, adiponectin secretion is markedly decreased
in patients with coronary artery disease compared to
those patients without the disease (23). 
Increases in epicardial adipose tissue seem to be
Figure 1 : Macroscopic appearance of epicardial fat
(A) Anterior view of a normal (210 g) heart. (B) Posterior view of
a normal (210 g) heart. (C) Anterior view of a hypertrophic (900
g) heart. (D) Posterior view of a hypertrophic (900 g) heart. Scale:
bar= 4 cm.                    .
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Figure 2 : Exposed
heart in an obese
individual undergoing
a triple coronary artery
bypass.
(A) Adipose tissue
deposited in the chest
under the skin
(subcutaneous). 
(B) Pericardial tissue.
(C) Epicardial adipose
tissue pulled up by
forceps (the adipose
tissue abnormally
covers entire heart in
this patient).28 McGill Journal of Medicine 2007
associated with abnormal cardiac morphology. Studies
show that epicardial adipose tissue is associated with
increased ventricular mass (17). A recent study we
conducted also demonstrates that atria enlargement and
impairment in diastolic filling is associated with
epicardial adipose tissue in morbidly obese subjects
(24).  
ECHOCARDIOGRAPHIC ASSESSMENT OF
EPICARDIAL ADIPOSE TISSUE
Epicardial fat thickness is measured on the free wall
of the right ventricle from both parasternal long- and
short-axis views (Figure 3) (15). The largest amount of
epicardial fat is usually seen at this right ventricular free
wall site. Epicardial adipose tissue is usually seen as an
echo-free or if it is massive, hyper-echoic space.  It is
important to ensure that epicardial fat thickness is not
measured obliquely since it falsely increases
measurements. Since there is some variation in the
longitudinal thickness of epicardial fat, three
measurements are usually taken and averaged in various
research studies that demonstrate the reliability of
epicardial fat thickness as a marker of visceral
adiposity. The reliability of epicardial adipose tissue
thickness on the free wall of the right ventricle is good
when comparing with baseline magnetic resonance
imaging (25). 
Echocardiography is non-invasive and safe. It is also
relatively cost and time efficient since it may be part of
the routine assessment that patients suspected to be at
risk for cardiovascular or metabolic illness undergo.
Only very few limitations exist. First, though epicardial
adipose tissue thickness is not as clearly measured as in
magnetic resonance imaging, as already mentioned, the
method is highly reliable. Second, at times it is possible
to confuse pericardial fluid with adipose tissue since the
fluid also shows up as relatively echo-free on an
echocardiograph (15).
EPICARDIAL ADIPOSE TISSUE'S
RELIABILITY AS A MARKER OF VISCERAL
ADIPOSITY
Several studies have demonstrated the reliability of
epicardial adipose tissue's thickness measurement via
echocardiography as a marker for visceral adiposity
(and the related metabolic and cardiovascular risk) (15,
17, 20, 24-27). Epicardial adipose tissue has been
shown to be very closely related to intra-abdominal
adiposity, a marker of entire body visceral adiposity,
according to various magnetic resonance imaging
studies (15, 20).  For example, an excellent correlation
between epicardial adipose tissue and waist
circumference (r = 0.895, p = 0.01) and magnetic
resonance image abdominal visceral adipose tissue (r =
0.864, p = 0.01) is reported (15). In the same study,
multiple regression analysis showed that epicardial
adipose tissue thickness was the strongest independent
variable correlated to magnetic resonance image
visceral adipose tissue (r2 = 0.442, p = 0.02) (15). 
Visceral adiposity is associated with features of
cardiovascular risk profile and metabolic syndrome (25-
27). Epicardial fat thickness has been shown to be
directly associated with many of these features that
include increased LDL cholesterol, fasting insulin (r2 =
0.387; P = 0.03), left ventricular mass (r = 0.755, p =
0.01) and diastolic blood pressure (r2 = 0. 387; P =
0.02), as well as decreased adiponectin (25, 26). 
Furthermore, waist-circumference, considered a good
indicator of visceral adiposity, is confounded by
subcutaneous abdominal fat thickness (28). It is well
known that visceral adiposity rather than subcutaneous
adiposity is more responsible for the health risks
associated with fat deposition in humans (29).
Epicardial adipose tissue measurements are not
confounded by sub-cutaneous fat (16). Thus, given the
poor reliability of waist circumference as a measure of
visceral adiposity, echocardiographic measurement of
visceral adipose tissue likely provides a truer visceral
fat content estimate.
FURTHER STUDY
The epicardial adipose tissue measurement via
echocardiography technique to predict visceral
adiposity and their associated health risks is relatively
young (the technique was suggested in 2003). Thus far,
various studies suggest it is an extremely useful and
effective method, and one that is increasingly important
as more and more anatomic, bimolecular, and clinical
relationships are found with epicardial adipose tissue
(26). Nevertheless, various questions remain
unanswered or are in the process of being answered in
various studies we are conducting. 
The use of the technique to measure epicardial adipose
tissue thickness, as well as the relationship between
Figure 3: Transthoracic echocardiogram (para-sternal long view)
showing a large area of epicardial adipose tissue (arrows) on free
wall of right ventricle.Echocardiographic Assessment of Epicardial Adipose Tissue 29 Vol. 10  No. 1
epicardial adipose tissue thickness and health risks, has
been mostly limited to European-Caucasian subjects.
Whether or not epicardial adipose tissue allows for
prediction of cardiometabolic alterations in non-
caucasian subjects remains to be determined. 
The use of epicardial adipose tissue thickness as
measured by echocardiography as an effective
therapeutic or physical health endpoint remains to be
determined. Often, exercise regimens may not decrease
a person's weight or "fatty" appearance. Physical
activity is shown to promote fat catabolism and muscle
anabolism (one reason for the constant weight).
Secondly, it is the visceral adiposity that is the
important marker of "health risks". Indeed, measuring
epicardial adipose tissue, a marker of visceral adiposity,
may be more important than using change in weight or
a less reliable measure of visceral adiposity as a marker
of cardiometabolic fitness.
Many questions remain about the molecular
relationships of epicardial adipose tissue that may
support the importance of measuring epicardial adipose
tissue thickness.  Additionally, studies on the
relationship of thickness of epicardial adipose tissue to
secretion of adipocytokines are limited (30-31).
Finally, various additional questions remain that will
be answered as further studies regarding epicardial
adipose tissue are conducted, including the reliability of
the echocardiographic technique between users and the
ability for widespread use of the techique.
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